- Pharmaceutical companies AstraZeneca and Merck said they had recorded positive results from a trial of a treatment of ovarian cancer.

The companies released positive results from a Phase III PAOLA-1 trial of Lynparza, also known as olaparib.

The treatment demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in women with newly-diagnosed advanced ovarian cancer.

The trial compared Lynparza when added to standard-of-care bevacizumab vurses bevacizumab alone in women in the first-line maintenance setting, irrespective of their genetic biomarker status or outcome from previous surgery.

Investigator-assessed results showed Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% -- equal to a hazard ratio of 0.59 -- and improved progression-free survival to a median of 22.1 months versus 16.6 months for those treated with bevacizumab alone.

At two years since trial initiation, 46% of women treated with Lynparza added to bevacizumab showed no disease progression versus 28% of women receiving bevacizumab alone.

Separately, AstraZeneca also announced positive survival results from a trial of a lung cancer treatment.

The Phase III FLAURA trial was of Tagrisso in first-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer.

Results showed a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint for Tagrisso versus gefitinib or erlotinib, both of which were previous standard-of-care treatments in this setting. At 8:03am: [LON:AZN] AstraZeneca PLC share price was -72p at 7311p

Story provided by